We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VABYSMO (Roche Products Pty Ltd)
Product name
VABYSMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
faricimab
Registration type
NCE/NBE
Indication
VABYSMO is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (nAMD),
- - Diabetic macular oedema (DMO).